Relatively high negative rate of mapping prostate biopsies has been a concern for many years. Also, due to the technique of such a biopsy, some areas of the prostate or suspicious lesions but small in size, where inaccessible. Moreover, these factors could have impact on detection of the actual prevalence of clinically significant prostate carcinoma. New techniques, such as fusion biopsy, are promising means to provide more accurate data in this field of interest. The aim of the study was to establish the utility of...

The site where the study was performed specializes in urology. On site besides MR scanner (1.5T GE HDxt system) there are facilities and equipment to perform transrectal and perineal biopsies, under general anesthesia when necessary. 35 patients with prostate adenocarcinoma histologically confirmed by mpMRI/US fusion biopsy were selected. They had PI-RADS v. 2.0 score of 3, 4 and 5 based on mpMRI examination performed according to PI-RADS guidelines (1). The mpMRI examinations comprised FSE, FSPGR and EPI sequences, T1w, T2w and CE images, DWI with...

Overall, prostate adenocarcinoma was found in 60 lesions of the 35 examined patients. All of them had fusion biopsy performed in targets located in either transition or peripheral zones. 4 of the 35 patients had lesions in both of these zones. 21 of the 60 lesions were located in transitional zone and remaining 39 in peripheral zone. Location and number of lesions assessed with regard to PI-RADS score are presented in table 1. Table 1. Location and PI-RADS score of the lesions with confirmed prostate...

On the basis of our observations the images crucial for target selection in TZ for mpMRI/US fusion biopsy were ADC maps. In significant number of lesions, hardly distinguishable in other sequences, ADC maps allowed to correctly chose and verify appropriate location for biopsy. Another key practical issue, having in our opinion, huge impact on the success of mpMRI/US fusion biopsy, is constant, on-demand, direct contact between radiologist and urologist on site. Directed obtaining of the specimen in mpMRI/US fusion biopsy allowed confirmation of prostate carcinoma...

web: zagrodzka.edu.pl Dr. Magdalena Zagrodzka (MD, PhD) Head of Diagnostic Imaging Department Voxel Diagnostic Medical Center Warsaw Koszykowa 78 00-671 Warsaw POLAND tel.: +48 (22) 494 36 15, +48 601 220714 mob.: +48 603 399 988 Email: [email protected]

1. Weinreb JC, Barentsz JO, Choyke PL et.al., PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2; Eur Urol. 2016 Jan;69(1):16-40